Skip to main content
Entheon Biomedical Corp. logo

Entheon Biomedical Corp. — Investor Relations & Filings

Ticker · ENBI LEI · 894500N2J7IXCCDRWU50 CSE Professional, scientific and technical activities
Open in API
Filings indexed 243 across all filing types
Latest filing 2025-07-19 Regulatory Filings
Country CA Canada
Listing CSE ENBI

About Entheon Biomedical Corp.

https://www.entheonbiomedical.com/

Entheon Biomedical Corp. is a biotechnology research and development company focused on creating therapeutic solutions for addiction and substance use disorders. The company specializes in the development and commercialization of psychedelic medicines, particularly dimethyltryptamine (DMT). Entheon aims to progress psychedelics to therapeutics by engineering proprietary drug discovery platforms, innovative drug delivery systems, and novel compounds tailored for treating these complex conditions.

Recent filings

Filing Released Lang Actions
52-109FV2 - Certification of interim filings - CFO (E).pdf
Regulatory Filings Classification · 1% confidence The document is a Form 52-109FV2: Certification of Interim Filings by the interim CFO, certifying the review and fair presentation of the interim financial report and interim MD&A. It does not include the interim report itself but is a statutory certification form required under NI 52-109. It therefore does not constitute the interim report (IR) itself nor an announcement of its publication, but rather a regulatory compliance filing. This falls into the fallback category "Regulatory Filings (RNS)".
2025-07-19 English
Interim MD&A - English.pdf
Management Reports Classification · 1% confidence The document is titled “Management Discussion and Analysis” and provides management’s narrative explanation of the company’s financial position, results of operations, forward-looking statements, corporate structure, liquidity and capital resources for the three and six months ended May 31, 2025 and 2024. This aligns exactly with the definition of an MD&A (“Management Reports”) rather than a full interim financial statement or an announcement of a report. Therefore, it should be classified as Management Reports (Code: MDA).
2025-07-19 English
Other.pdf
Interim / Quarterly Report Classification · 1% confidence The document is a 'Form 5 - Quarterly Listing Statement' filed by Entheon Biomedical Corp. It explicitly includes schedules for unaudited interim financial statements (Schedule A) and Management Discussion and Analysis (Schedule C) for the period ended May 31, 2025. While it acts as a cover form, it contains the substantive financial data and analysis required for an interim report. Therefore, it is classified as an Interim/Quarterly Report (IR). Q2 2025
2025-07-19 English
Statement of executive compensation (form 51-102F6V) - English.pdf
Remuneration Information Classification · 1% confidence The document is a detailed disclosure of executive and director compensation, outlining salaries, bonuses, stock option plans, and employment agreements for named executive officers and directors for the fiscal year. This aligns with remuneration information requirements, similar to proxy statement compensation disclosures. It does not present full financial statements or minutes of a meeting, nor is it an earnings release or management discussion; it specifically focuses on executive compensation. The appropriate category is Remuneration Information (DEF 14A).
2025-04-16 English
News release - English.pdf
Board/Management Information Classification · 1% confidence The document is a press release announcing the appointment of Harrison Newlands to the Board of Directors and the resignation of another director. It clearly signals a change in the company’s board composition, which falls under Board/Management Information (change of directors).
2025-04-07 English
Interim financial statements/report – English.pdf
Interim / Quarterly Report Classification · 1% confidence The document is titled 'Condensed Interim Consolidated Financial Statements' for Entheon Biomedical Corp. for the three-month period ended February 28, 2025. It contains comprehensive financial statements (Statement of Financial Position, Statement of Loss and Comprehensive Loss, Statement of Changes in Equity, and Statement of Cash Flows) along with detailed notes to the financial statements. It is not an announcement or a summary, but the full interim report itself, fitting the definition of an Interim/Quarterly Report (IR). Q4 2025
2025-04-01 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.